Reviva Pharmaceuticals reported a net loss of $7.9 million for the nine months ended September 30, 2026, a significant reduction from the $16.5 million loss in the prior year period. The company strengthened its liquidity through public and ATM offerings, ending the quarter with $17.5 million in cash and cash equivalents.
Reviva Pharmaceuticals reported a net loss of $2.3 million for the third quarter of 2026, an improvement from a $4.0 million loss in the prior year period. The company is awaiting FDA feedback in Q4 2026 regarding a new formulation of brilaroxazine for its Phase 3 RECOVER-2 trial in schizophrenia. Reviva also noted it has filed a new composition of matter patent application that could extend protection for brilaroxazine through 2046.
Term
Q3 2026
“Our near-term focus is obtaining Food and Drug Administration (FDA) feedback on the proposed use of a new formulation of brilaroxazine and preparing for the next stages of clinical development while managing our capital resources carefully.”
Laxminarayan Bhat, Founder, President, and CEO of Reviva
“We remain focused on disciplined execution as we advance brilaroxazine as a potentially differentiated treatment option for patients with schizophrenia.”
Laxminarayan Bhat, Founder, President, and CEO of Reviva